Page 1 of 23
F.C. ODDS - PUBLICATIONS
Books/Monographs, etc.
2002
1997
1996
1993
1989
1988
1979
1976
2008
2008
2007
2007
2006
2006
2006
2005
Odds, F.C., Johnson, E.R., Barnes, R.A. (eds) AmBisome®: An
International Workshop. Journal of Antimicrobial Chemotherapy 49 (suppl
1).
Vanden Bossche, H., Odds, F.C., Stevens, D.A. (eds.) Host-fungus
interplay. National Foundation for Infectious Diseases, Bethesda, MD.
Kibbler, C.C., Mackenzie, D.W.R., Odds, F.C. (eds.) Principles and
practice of clinical mycology. J. Wiley & Sons, Chichester.
Vanden Bossche, H., Odds, F.C., Kerridge, D. (eds.) Dimorphic fungi in
biology and medicine. Plenum Press, New York and London.
Kobayashi, G.S., Odds, F.C. (guest editors) Current perspectives on
antifungal susceptibility testing. Scientific Therapeutics Information, Inc.,
Springfield, New Jersey (30 pages).
Odds, F.C. Candida and candidosis, 2nd ed. (489 pages, 5790 refs.)
Bailliere-Tindall, London.
Odds, F.C. Candida and candidosis. (382 pages, 2265 refs.). Leicester
University Press, Leicester. (Published in North America by University
Park Press, Baltimore, MD, U.S.A.).
E.G.V. Evans (ed.) Serology of fungal infection and farmer's lung disease.
British Society for Mycopathology, Leeds. (Co-author as member of
Working Party on fungal antigens.).
Articles/book chapters
Odds, F.C., Jacobsen, M.D. Multi-locus sequence typing of pathogenic
Candida species. Eukaryotic Cell (in press).
Naglik, J., Fidel, P., Odds, F.C. Animal models of mucosal Candida
infection. FEMS Microbiol. Lett. (in press).
Odds, F.C. The evolution of pathogenic Candida species. In Baquero, F.,
Nombela, C., Cassel, G.H., Gutierrez, J.A. (eds.) Evolutionary Biology of
Bacterial and Fungal Pathogens. pp565–578, ASM Press, Washington.
Brown, A.J.P., Odds, F.C., Gow, N.A.R. Infection-related gene
expression in Candida albicans. Current Opinion in Microbiology 10,
307–313.
Odds, F.C., Gow, N.A.R., Brown, A.J.P. Towards a molecular
understanding of Candida albicans virulence. In Heitman, J., Filler, S.,
Mitchell, A. (eds.) Molecular Principles of Fungal Pathogenesis, pp. 305–
320. ASM Press, Washington, DC.
Odds, F.C. Genomics, molecular targets and the discovery of antifungal
drugs. Revista Iberoamericana de Micología 22, 229–237.
Odds, F.C. Drug evaluation: BAL-8557 — a novel broad-spectrum
triazole antifungal. Current Opinion in Investigational Drugs 7, 766–772.
Odds, F.C. Antifungal agents: resistance and rational use. In I.M. Gould
and J.W.M. Van der Meer (eds) Antibiotic policies: theory and practice, pp.
311–330. Kluwer Academic/Plenum Publishers, New York.
Page 2 of 23
2004
2003
2003
2003
2003
2003
2003
2003
2002
2002
2001
2001
2001
2001
2001
2001
2000
2000
Odds, F.C., Brown, A.J.P., Gow, N.A.R. Candida albicans genome
sequence: a platform for genomics in the absence of genetics. Genome
Biology 5, 230.1–230.3.
Odds, F.C., Hube, B., Calderone, R.A., Nombéla, C. Virulence in
Candida species: views and suggestions from a peer-group workshop ASM
News 69, 54–55.
Odds, F.C., Brown, A.J.P., Gow, N.A.R. Antifungal agents: mechanisms
of action. Trends in Microbiology 11, 272–279.
Odds, F.C. Synergy, antagonism, and what the chequerboard puts between
them (editorial). Journal of Antimicrobial Chemotherapy 52, 1.
Odds, F.C. Reflections on the question: What does molecular mycology
have to do with the clinician treating the patient? Medical Mycology 41, 1–
6.
Odds, F.C. Editorial commentary: fluconazole plus amphotericin B
combinations are not contraindicated and may add benefit for treatment of
candidemia. Clinical Infectious Diseases 36, 1229–1230.
Odds, F.C. Coccidioidomycosis: flying conidia and severed heads. The
Mycologist 17, 37–40.
Odds, F.C. Antifungal agents: their diversity and increasing sophistication.
The Mycologist 17, 51–55.
Sanglard, D., Odds, F.C. Resistance of Candida species to antifungal
agents: molecular mechanisms and clinical consequences. The Lancet
Infectious Diseases 2, 73–85.
Gow, N.A.R., Brown, A.J.P., Odds, F.C. Fungal morphogenesis and host
invasion. Current Opinion in Microbiology 5, 366–371.
Walsh, T.J., Viviani, M.-A., Arathoon, E., Chiou, C., Ghannoum, M.,
Groll, A.H., Odds, F.C. New targets and delivery systems for antifungal
therapy. Medical Mycology 38 (suppl. 1), 335–347.
Rex, J.H., Pfaller, M.A., Walsh, T.J., Chaturvedi, V. Espinel-Ingroff,
A., Ghannoum, M.A., Gosey, L.L., Odds, F.C., Rinaldi, M.G., Sheehan,
D.J., Warnock, D.W. Antifungal susceptibility testing: practical aspects
and current challenges. Clinical Microbiology Reviews 14, 643–658.
Odds, F.C., Gow, N.A.R., Brown, A.J.P. Fungal virulence studies come
of age. Genome Biology 2, 1009.1–1009.4.
Odds, F.C. Sordarin antifungal agents. Expert Opinion on Therapeutic
Patents 11, 283–294.
Odds, F.C. In vitro susceptibility testing of antifungal agents: are the
results of relevance to clinical decision making? In: The Effective
Prevention and Management of Systemic Fungal Infection in
Haematological Malignancy (A. Prentice, T. Rogers, A. Miles, eds.). UK
Key Advances in Clinical Practice Series 2001; Aesculapius Medical Press,
pp. 111–116.
Finquelievich, J.L., Odds, F.C., Queiroz-Telles, F., Wheat, L.J. New
advances in antifungal treatment. Medical Mycology 38 (suppl. 1), 317–
322.
Odds, F.C., Brown, A.J.P., Gow, N.A.R. Might Candida albicans be
made to mate after all? Trends in Microbiology 8, 4–6.
Odds, F.C. Pathogenic fungi in the 21st century. Trends in Microbiology
8, 201–208.
Page 3 of 23
2000
2000
1999
1998
1998
1998
1998
1997
1997
1997
1997
1997
1996
1996
1996
1996
1996
Odds, F.C. Are molecular methods the optimum route to new
antimicrobial agents? In Andrew, P.W., Oyston, P., Smith, G.L., StewartTull, D.E. (eds). Fighting Infection in the 21st Century pages 237–258.
Blackwell Science, Oxford.
Gow, N.A.R., Brown, A.J.P., Odds, F.C. Candida’s arranged marriage.
Science 289, 256–257.
Odds, F.C. Editorial overview [editorial]. Current Opinion in Antiinfective Investigational Drugs 1, 296.
Odds, F.C. Should resistance to azole antifungals in vitro be interpreted as
predicting clinical non-response. DrugResistance Updates 1, 11–15.
Odds, F.C. Fungal dimorphism [editorial]. Journal de Mycologie
Médicale 8, 55–56.
Hube, B, Sanglard, D., Schaller, M., Ibrahim, A., Odds, F.C., Gow,
N.A.R. What are the functions of six different genes encoding secreted
proteinases in Candida albicans. Mycoses 41 (suppl. 1), 47–50.
Hube, B, Rüchel, R., Monod, M., Sanglard, D., Odds, F.C. Functional
aspects of secreted Candida proteinases. Advances in Experimental Biology
and Medicine 436, 339–344.
Odds, F.C. The role of antifungal drug evaluation in vitro in the treatment
of mycoses. Advances in Medical Mycology (in press).
Odds, F.C. Switch of phenotype as an escape mechanism of the intruder.
Mycoses 40 (suppl. 2), 9–12.
Odds, F.C. Strain typing of Candida albicans. In Jacobs, P., Nall, L. (eds.)
Biomedical mycology pages 357–374. Marcel Dekker, Inc., New York.
Odds, F.C. Personal opinion: can antifungal sensitivity tests predict
clinical treatment outcomes? Revista Iberoamericana de Micología 14, 83–
84.
Odds, F.C. Mycology in oral pathology. Acta Stomatologica Belgica 94,
75–80.
Overdijk, B., Van Steijn, G.J., Odds, F.C. Chitinase levels in guinea pig
blood are increased in experimentally induced aspergillosis. In: Muzzarelli,
R.A.A. (ed) Chitin Enzymology, vol. 2, pp. 21–35. Atec Edizioni, Italy.
Odds, F.C., Rinaldi, M.G. Nomenclature of fungal diseases. In Borgers,
M., Hay, R.J., Rinaldi, M.G. (eds). Current Topics in Medical Mycology
volume 6, pp. 33–46. JR Prous, Barcelona.
Odds, F.C. The fungal kingdom: essentials of medical mycology. In
Kibbler, C.C., Mackenzie, D.W.R.M., Odds, F.C. (eds). Principles and
Practice of Clinical Mycology pages 1–6. J. Wiley & Sons, Chichester.
Odds, F.C. Medical mycology and the millenium. Revista Iberoamericana
de Micología 13, S69–S70.
Odds, F.C. Epidemiological shifts in opportunistic and nosocomial
Candida infection: mycological aspects. International Journal of
Antimicrobial Agents 6, 141–144.
Page 4 of 23
1996
1995
1995
1995
1995
1994
1994
1994
1994
1994
1994
1994
1994
1994
1994
1994
1993
1993
Odds, F.C. Antifungal therapy. In Kibbler, C.C., Mackenzie, D.W.R.M.,
Odds, F.C. (eds). Principles and Practice of Clinical Mycology pages 35–
48. J. Wiley & Sons, Chichester.
Vanden Bossche, H., Warnock, D.W., Dupont, B., Kerridge, D., Gupta,
S.S., Improvisi, L., Marichal, P., Odds, F.C., Provost, F., Ronin, O.
Mechanisms and clinical impact of antifungal drug resistance. Journal of
Medical and Veterinary Mycology 32 (spl 1), 189–202.
Odds, F.C. Resistencia a los agentes antifúngicos de las levaduras de
interés clinico. Revista Clinica Española 195, 56–57.
Odds, F.C. Les agents antifungiques, leur passé, leur présent et leur avenir.
Bulletin de la Société Françcaise de Microbiologie Médicale 10, 285–293.
Odds, F.C. Cambios en la epidemiología de las infecciones oportunistas
por Candida. Revista Clinica Española 195, 1–3.
Vanden Bossche, H., Marichal, P., Odds, F.C. Molecular mechanisms of
drug resistance in fungi. Trends in Microbiology 2, 393-400.
Odds, F.C. Systemic mycoses and their management. Forum (in press).
Odds, F.C. Pathogenesis of Candida infections. Journal of the American
Academy of Dermatology 31, S2-S5.
Odds, F.C. Nomenclatura delle micosi, In L. Ajello, C. Farina, A.
Mazzoni, G. Picerno (eds) Fondamenti di micologia clinica Associazione
Microbiologi Clinici Italiani, Milano, pp. 103-116.
Odds, F.C. New aspects of the epidemiology of Candida infections. In
Nelwan, R.H.H. (ed). Proceedings of the 3rd Western Pacific Congress on
Chemotherapy and Infectious Diseases — Bali 1992 pages 265–269.
Odds, F.C. Laboratory evaluation of antifungal agents in vitro. Infectious
Diseases in Clinical Practice 3 (suppl. 2), S90–S96.
Odds, F.C. Implications of resistance and trends in the epidemiology of
mycoses. Clinician 11, 14–18.
Odds, F.C. Implications of resistance and trends in the epidemiology of
mycoses. Clinician 11, 14–18.
Odds, F.C. Candida species and virulence. ASM News 60, 313-318.
Odds, F.C. Candida albicans, the life and times of a pathogenic yeast.
Presidential address. Journal of Medical and Veterinary Mycology 32 (spl
1), 1–8.
Agabian, N., Odds, F.C., Poulain, D., Soll, D.R., White, T.C.
Pathogenesis of invasive candidiasis. Journal of Medical and Veterinary
Mycology 32 (spl 1), 229–238.
Odds, F.C. & Van Cutsem, J. Itraconazole — preclinical data in vitro and
in vivo in cutaneous and other superficial mycoses. In J. Rippon & R.P.
Fromtling (eds) Cutaneous Antifungal Agents, pp. 251–261.
Odds, F.C. Vulvovaginale Candida-Infektion: Aspekte der Epidemiologie,
Pathogenese und Behandlung. International Journal of Feto-Maternal
Medicine 6 (suppl 1), 19-24.
Page 5 of 23
1993
1993
1993
1993
1993
1993
1993
1993
1992
1992
1991
1991
1991
1991
1990
1990
Odds, F.C. Vulvovaginal Candida infection: aspects of epidemiology,
pathogenesis and management. International Journal of Experimental and
Clinical Chemotherapy 5, 65–72.
Odds, F.C. Spectrum of orally active antifungals. Journal of the European
Academy of Dermatology and Venereology. 2 (suppl 1), S12-S18.
Odds, F.C. Spectrum of orally active antifungals. In W.H.C. Burgdorf &
S.I.Katz (eds) Dermatology: progress and perspectives. Parthenon
Publishing Group, New York, pp. 277–279.
Odds, F.C. Resistance of yeasts to azole-derivative antifungals. Journal of
Antimicrobial Chemotherapy 31, 463-471.
Odds, F.C. Quantification of Candida morphology in vitro and in vivo. In
H. Vanden Bossche, F.C. Odds and D. Kerridge (eds) Dimorphic fungi in
biology and medicine Plenum Press, New York and London, pp. 145–152.
Odds, F.C. Morphological change in Candida albicans. Jpn. J. Med.
Mycol. 34, 99-111.
Odds, F.C. Itraconazole — a new oral antifungal agent with a very broad
spectrum of activity in superficial and systemic mycoses. Jourrnal of
Dermatological Science 5, 65-72.
Odds, F.C. Epidemiology and diagnosis of vulvovaginal Candida
infections. International Journal of Feto-Maternal Medicine 5, 151-153.
Odds, F.C., Brawner, D.L., Staudinger, J., Magee, P.T. & Soll, D.R.
Typing of Candida albicans strains. Journal of Medical and Veterinary
Mycology 30 (suppl 1), 87-94.
Odds, F.C. Candida infection in AIDS patients. International Journal of
STD & AIDS 3, 157-160.
Odds, F.C. Sabouraud('s) agar. Journal of Medical and Veterinary
Mycology 29, 355-359.
Hube, B., Turver, C.J., Odds, F.C., Eiffert, H., Boulnois, G.J., Köchel,
H., Rüchel, R. Identifizierung, Klonierung und Charakterisierung des Gens
der sekretorischen Aspartat-Protease von Candida albicans. Mycoses 34
(suppl. 1), 59–61.
Odds, F.C. Potential for penetration of passive barriers to fungal invasion
in humans. In: G.T. Cole & H.C. Hoch (eds.) The fungal spore and disease
initiation in plants and animals, pp. 287-295. Plenum Press, New York.
Odds, F.C. Perspective of the application of molecular biology techniques
in the study of Candida. In: E. Tumbay, H.P.R. Seeliger & O. Ang (eds.)
Candida and candidamycosis. FEMS Symposium No. 50., pp. 5–11.
Plenum Press, New York.
Odds, F.C., Schmid, J. & Soll, D.R. Epidemiology of Candida infections
in AIDS. In H. Vanden Bossche, D.W.R. Mackenzie, G. Cauwenbergh, J.
Van Cutsem, E. Drouhet & B. Dupont (eds.) Mycoses in AIDS Patients, pp.
67-74. Plenum Press, New York.
Odds, F.C. Role of in-vitro evaluation for therapeutic decisions in
candidosis. In: Therapy of candidosis: from screening to clinical
evaluation (Proceedings of a satellite symposium of the FEMS Symposium
Page 6 of 23
1990
1989
1989
1987
1987
1986
1986
1985
1985
1985
1985
1984
1981
1981
1977
on Candida and candidamycosis) pp. 44-47. Janssen Pharmaceutica,
Belgium.
Odds, F.C. Biologie moléculaire dans l'étude de Candida. Bulletin de la
Société Française de Mycologie Médicale 19, 5-12.
Odds, F.C. Facteurs d'inhibition relative: une nouvelle approche de
l'evaluation in vitro des antibiotiques antifongiques. Annales de
Dermatologie et Véneréologie 116 (suppl. 1), 10-12.
Odds, F.C. Candidiasis cutánea y mucosa: Etiología y patogenia. Drugs of
Today 25 (suppl. 9), 33-37.
Odds, F.C. Progrés récents dans la biologie des Candida. Annales de
Biologie Clinique 45, 553-557.
Odds, F.C. Candida infections: an overview. CRC Critical Reviews in
Microbiology 15, 1-6.
Odds, F.C. Summing up and outlook. In: K. Iwata & H. Vanden Bossche
(eds.) In vitro and in vivo evaluation of antifungal agents, 299-303.
Elsevier Science Publishers B.V., Amsterdam.
Odds, F.C. A survey of old and new antifungal tests in vitro. In: K. Iwata
& H. Vanden Bossche (eds.) In vitro and in vivo evaluation of antifungal
agents, 13-19. Elsevier Science Publishers B.V., Amsterdam.
Odds, F.C. Morphogenesis in Candida albicans. CRC Critical Reviews in
Microbiology 12, 45-93.
Odds, F.C. Laboratory tests for the activity of imidazole and triazole
antifungal agents in vitro. Seminars in Dermatology 4, 260-269.
Odds, F.C. Candida albicans proteinase as a virulence factor in the
pathogenesis of Candida infections. Zentralblatt fur Bakteriologie und
Hygiene A 260, 539-542.
Odds, F.C. Biotyping of medically important fungi. In: M.R. McGinnis
(ed.) Current Topics in Medical Mycology 1, 155-171.
Odds, F.C. Ecology and epidemiology of Candida species. Zentralblatt
fur Bakteriologie A 287, 207-212.
Odds, F.C. The pathogenesis of candidosis. Hospital Update 7, 935-945.
Odds, F.C. Studies with ketoconazole in vitro. Clinical Research Reviews
1, 173-175.
Odds, F.C. Management and treatment of candidosis. Medical News,
March 2, 10-11.
Page 7 of 23
Original papers in peer-reviewed scientific journals
2008
2008
2008
2008
2008
2007
2007
2007
2007
2007
2007
Jacobsen, M.D., Davidson, A.D., Li, S.-Y., Shaw, D.J., Gow, N.A.R.,
OddS, F.C. Molecular phylogenetic analysis of Candida tropicalis isolates
by multi-locus sequence typing. Fungal Genetics and Biology (in press).
Jacobsen, M.D., Boekhout, T., Odds, F.C. Multilocus sequence typing
reveals synonymy and indicates differences between Candida albicans and
Candida stellatoidea. FEMS Yeast Research (in press).
De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E.,
Calandra, T., Pappas, P.G., Maertens, J., Lortholary, O., Kauffman,
C.A., Denning, D.W., Patterson, T.F., Maschmeyer, G., Bille, J.,
Dismukes, W.E., Herbrecht, R., Hope, W.W. Kibbler, C.C., Kullberg,
B.-J., Marr, K.A., Muñoz, P., Odds, F.C., Perfect, J.R., Restrepo, A.,
Ruhnke, M., Segal, B.H., Sobel, J.D., Sorrell, T.C., Viscoli, C.,
Wingard, J.R., Zaoutis, T., Bennett, J.E. Revised definitions of the
EORTC/MSG Consensus 1 Group for invasive fungal diseases. Clinical
Infectious Diseases (in press).
Takakura, S., Ichiyama, S., Bain, J.M., Davidson, A.D., Jacobsen,
M.D., Shaw, D.J., Gow, N.A.R., Odds, F.C. Comparison of Candida
albicans strain types among isolates from three countries. International
Journal of Medical Microbiology (in press).
Strijbis, K., van Roermund, C.W.T., Visser, W.F., Mol, E.C., van den
Burg, J., MacCallum, D.M., Odds, F.C., Paramonova, E., Krom, B.P.,
Distel, B. Carnitine-dependent transport of acetyl-CoA in Candida
albicans is essential for growth on non-fermentable carbon sources and
contributes to biofilm formation. Eukaryotic Cell 7, 610–618.
Odds, F.C., Hanson, M.F., Davidson, A.D., Jacobsen, M.D., Wright, P.,
Whyte, J.A., Gow, N.A.R., Jones, B.L. One-year prospective survey of
Candida bloodstream infections in Scotland. Journal of Medical
Microbiology 56, 1066–1075.
Odds, F.C., Bougnoux, M.-E., Shaw, D.J., Bain, J.M., Davidson, A.D.,
Diogo, D., Jacobsen, M.D., Lecomte, M., Li, S.-Y., Tavanti, A., Maiden,
M.C.J., Gow, N.A.R., d’Enfert, C. Molecular phylogenetics of Candida
albicans. Eukaryotic Cell 6, 1041–1052.
Mora-Montes, H., Bates, S., Netea, M.G., Díaz-Jiménez, D.F., LópezRomero, E., Zinker, S., Ponce-Noyola, P., Kullberg, B.-J., Brown,
A.J.P., Odds, F.C., Flores-Carreón, A., Gow, N.A.R. The endoplasmic
reticulum α-glycosidases of Candida albicans are required for Nglycosylation, cell wall integrity and normal host-fungus interaction.
Eukaryotic Cell 6, 2184–2193.
Kunze, D., MacCallum, D., Odds, F.C., Hube, B. Multiple functions of
DOA1 in Candida albicans. Microbiology 153, 1026–1041.
Jacobsen, M.D., Whyte, J.A., Odds, F.C. Candida albicans and Candida
dubliniensis respond differently to echinocandin antifungal agents in vitro
Antimicrobial Agents and Chemotherapy 51, 1882–1884.
Jacobsen, M.D., Gow, N.A.R., Maiden, M.C.J., Shaw, D.J., Odds, F.C.
Strain typing and determination of population structure of Candida krusei
by multilocus sequence typing. Journal of Clinical Microbiology 45, 317–
323.
Page 8 of 23
2007
2007
2007
2007
2007
2007
2007
2007
2007
2007
2006
2006
Jacobsen, M.D., Davidson, A.D., Li, S.-Y., Shaw, D.J., Gow, N.A.R.,
OddS, F.C. Molecular phylogenetic analysis of Candida tropicalis isolates
by multi-locus sequence typing. Fungal Genetics and Biology (in press).
Jacobsen, M.D., Boekhout, T., Odds, F.C. Multilocus sequence typing
reveals synonymy and indicates differences between Candida albicans and
Candida stellatoidea. FEMS Yeast Research (in press).
Gow, N.A.R., Netea, M.G., Munro, C.A., Ferwerda, G., Bates, S., MoraMontes, H., Walker, L., Jansen, T., Jacobs, L., Tsoni, V., Brown, G.D.,
Odds, F.C., Van der Meer, J.W.M., Brown, A.J.P., Kullberg, B.-J.
Recognition of Candida albicans β-glucan by dectin-1 induces cytokines
and has non-redundant effects on the activation of innate immunity.
Journal of Infectious Diseases 196, 1566–1571.
Enjalbert, B., MacCallum, D.M., Odds, F.C., Brown, A.J.P. Nichespecific activation of the oxidative stress response by the pathogenic fungus
Candida albicans. Infection and Immunity 75, 2143–2151.
De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E.,
Calandra, T., Pappas, P.G., Maertens, J., Lortholary, O., Kauffman,
C.A., Denning, D.W., Patterson, T.F., Maschmeyer, G., Bille, J.,
Dismukes, W.E., Herbrecht, R., Hope, W.W. Kibbler, C.C., Kullberg,
B.-J., Marr, K.A., Muñoz, P., Odds, F.C., Perfect, J.R., Restrepo, A.,
Ruhnke, M., Segal, B.H., Sobel, J.D., Sorrell, T.C., Viscoli, C.,
Wingard, J.R., Zaoutis, T., Bennett, J.E. Revised definitions of the
EORTC/MSG Consensus 1 Group for invasive fungal diseases. Clinical
Infectious Diseases (in press).
Chaves, G.M., Bates, S., MacCallum, D.M., Odds, F.C. Candida
albicans GRX2, encoding a putative glutaredoxin, is required for virulence
in a murine model. Genetics and Molecular Research 6, 1051–1063.
Bates, S., de la Rosa, J.M., MacCallum, D.M., Brown, A.J.P., Gow,
N.A.R., Odds, F.C. Candida albicans Iff11, a secreted protein required for
cell wall structure and virulence. Infection and Immunity 75, 2922–2928.
Barelle, C.J., Duncan, V.M.S., Brown, A.J.P., Gow, N.A.R., Odds, F.C.
Azole antifungals induce upregulations of SAP4, SAP5 and SAP6 secreted
proteinase genes in filamentous Candida albicans cells in vitro and in vivo.
Journal of Antimicrobial Chemotherapy 61, 315–322.
Bain, J.M., Tavanti, A., Davidson, A.D., Jacobsen, M.D., Shaw, D.,
Gow, N.A.R., Odds, F.C. Multilocus sequence typing of the pathogenic
fungus Aspergillus fumigatus. Journal of Clinical Microbiology 45, 1469–
1477.
Argimón, S., Wishart, J.A., Leng, R., Macaskill, S., Mavor, A.,
Alexandris, T., Nicholls, S., Knight, A.W., Enjalbert, B., Walmsley, R.,
Odds, F.C., Gow, N.A.R., Brown, A.J.P. Developmental regulation of an
adhesin gene during cellular morphogenesis in the fungal pathogen Candida
albicans. Eukaryotic Cell 6, 682–692.
Piekarska, K., Mol, E., van den Berg, M., Hardy, G., van den Burg, J.,
van Roermun, C., MacCallum, D., Odds, F., Distel, B. Peroxisomal fatty
acid -oxidation is not essential for virulence of Candida albicans.
Eukaryotic Cell 5, 1847–1856.
Pfaller, M.A., Diekema, D.J., Rex, J.H., Espinel-Ingroff, A, Johnson,
E.M., Andes, D., Chaturvedi, V., Ghannoum, M.A., Odds, F.C.,
Rinaldi, M.G., Sheehan, D.J., Troke, P., Walsh, T.J., Warnock, D.W.
Page 9 of 23
2006
2006
2006
2006
2006
2005
2005
2005
2005
2005
Correlation of MIC with outcome for Candida species tested against
voriconazole: analysis and proposal for interpretive breakpoints. Journal of
Clinical Microbiology 44, 819–826.
Odds, F.C., Davidson, A.D., Jacobsen, M. D., Tavanti, A., Whyte, J.A.,
Kibbler, C.C., Ellis, D.H., Maiden, M.C.J., Shaw, D.J., Gow, N.A.R.
Candida albicans strain maintenance, replacement, and microvariation
demonstrated by multilocus sequence typing. Journal of Clinical
Microbiology 44, 3647–3658.
MacCallum, D.M., Findon, H., Kenny, C.C. Butler, G., Haynes, K.,
Odds, F.C. Different consequences of ACE2 and SWI5 gene disruptions for
virulence of pathogenic and nonpathogenic yeasts. Infection and Immunity
74, 5244–5248.
Chen, K.-W., Chen, Y.-C., Lo, H.-J., Odds, F.C., Wang, T.-H., Lin, C.Y., Li, S.-Y. Multilocus sequence typing for analyses of clonality of
Candida albicans strains in Taiwan. Journal of Clinical Microbiology 44,
2172–2178.
Bates, S. Hughes, H.B., Munro, C.A., Thomas, W.P.H., MacCallum,
D.M., Bertram, G., Atrih, A., Ferguson, M.A.J., Brown, A.J.P., Odds,
F.C., Gow, N.A.R. Outer chain N-glycans are required for cell wall
integrity and virulence of Candida albicans. Journal of Biological
Chemistry 281, 90–98.
Barelle, C.J., Manson, C.L., MacCallum, D.M., Gow, N.A.R. Odds,
F.C. Brown, A.J.P. Niche-specific regulation of central metabolic
pathways in a fungal pathogen. Cellular Microbiology 8, 961–971.
Tournu, H., Tripathi, G., Bertram, G., Macaskill, S., Mavor, A.,
Walker, L., Odds, F.C., Gow, N.A.R., Brown, A.J.P. . Global regulation
of the protein kinase Gcn2 in the human pathogen Candida albicans.
Eukaryotic Cell 4, 1687–1696.
Tavanti, A., Davidson, A.D., Johnson, E.M., Maiden, M.C.J., Shaw,
D.J., Gow, N.A.R., Odds, F.C. Multilocus sequence typing for
differentiation of strains of Candida tropicalis. Journal of Clinical
Microbiology 43, 5593–5600.
Tavanti, A., Davidson, A.D., Gow, N.A.R., Maiden, M.C.J., Odds, F.C.
Candida orthopsilosis and Candida metapsilosis, spp. nov., to replace
Candida parapsilosis groups II and III. Journal of Clinical Microbiology
43, 284–292.
Tavanti, A., Davidson, A.D., Fordyce, M.J., Gow, N.A.R., Maiden,
M.C.J., Odds, F.C. Candida albicans: populations and properties
determined by multi-locus sequence typing. Journal of Clinical
Microbiology 43, 5601–5613.
Munro, C.A., Bates, S., Buurman, E.T., Hughes, H.B., MacCallum,
D.M., Bertram, G., Atrih, A., Ferguson, M.A.J., Bain, J.M., Brand, A.,
Hamilton, S., Westwater, C., Thomson, L.M., Brown, A.J.P., Odds,
F.C., Gow, N.A.R. Mnt1p and Mnt2p of Candida albicans are partially
redundant -1,2-mannosyltranferases that participate in O-linked
mannosylation and are required for adhesion and virulence. Journal of
Biological Chemistry 280, 1051–1060.
Page 10 of 23
2005
2005
2005
2005
2005
2005
2005
2005
2004
2004
2004
Meerpoel, L., Backx, L.J.J., Van der Veken, L.J.E., Heeres, J., Corens,
D., De Groot, A., Odds, F.C., Van Gerven, F., Woestenborghs, F.A.A.,
Van Breda, A., Oris, M., van Dorsselaer, P., Willemsens, G.H.M.,
Vermuyten, K.J.P., Marichal, P.J.M.G., Vanden Bossche, H.F., Ausma,
J., Borgers, M. Synthesis and in vitro and in vivo structure-activity
relationships of novel antifungal triazoles for dermatology. Journal of
Medicinal Chemistry 48, 2184–2193.
MacCallum, D.M., Whyte, J.A., Odds, F.C. Efficacy of caspofungin and
voriconazole combinations in experimental aspergillosis. Antimicrobial
Agents and Chemotherapy 49, 3697–3701.
MacCallum, D.M., Odds, F.C. Temporal events in the intravenous
challenge model for experimental Candida albicans infections in female
mice. Mycoses 48, 151–161.
Kunze, D., Melzer, I., Bennett, D., Sanglard, D., MacCallum, D.,
Nörskau, J., Coleman, D.C., Odds, F.C., Schäfer, W., Hube, B.
Functional analysis of the phospholipase C gene CaPLC1 and two unusual
phopholipase C genes, CaPLC2 and CaPLC3, of Candida albicans.
Microbiology 151, 3381–3394.
Fradin, C., MacCallum, D.M., Odds, F.C., Hube, B. Granulocytes
govern the transcriptional response, morphology and proliferation of
Candida albicans in human blood. Molecular Microbiology 56, 397–415.
Copping, V.M.S., Barelle, C.J., Hube, B., Gow, N.A.R., Brown, A.J.P.,
Odds, F.C. Exposure of Candida albicans to antifungal agents affects
expression of SAP2 and SAP9 secreted proteinase genes. Journal of
Antimicrobial Chemotherapy 55, 645–654.
Bates, S., MacCallum, D.M., Bertram, G., Munro, C.A., Hughes, H.B.
Buurman, E.T., Brown, A.J.P., Odds, F.C., Gow, N.A.R. Candida
albicans Pmr1p, a secretory pathway Ca2+/Mn2+ P-type ATPase, is required
for glycosylation and virulence. Journal of Biological Chemistry 280,
23408–23415.
Albrecht, A., Felk, A., Pichova, I., Naglik, J.R., Schaller, M., de Groot,
P., MacCallum, D., Odds, F.C., Schäfer, W., Klis, F., Monod, M., Hube,
B. Glycosylphosphatidylinositol-anchored proteases of Candida albicans
target proteins necessary for both cellular processes and host-pathogen
interactions. Journal of Biological Chemistry 281, 688–694.
Vanden Bossche, H., Ausma, J., Bohets, H., Vermuyten, K.,
Willemsens, G., Marichal, P., Meerpoel, L., Odds, F., Borgers, M. The
novel azole R126638 is a selective inhibitor of ergosterol synthesis in
Candida albicans, Trichophyton spp. and Microsporum canis.
Antimicrobial Agents and Chemotherapy 48, 3272–3278.
Tavanti, A., Gow, N.A.R., Maiden, M.J., Odds, F.C., Shaw, D.J.
Genetic evidence for recombination in Candida albicans based on
haplotype analysis. Fungal Genetics and Biology 41, 553–562.
Sendid, B., Jouault, T., Coudriau, R., Camus, D., Odds, F., Tabouret,
M., Poulain, D. Increased sensitivity of mannanemia detection tests by
joint detection of alpha- and beta-linked oligomannosides during
experimental and human systemic candidiasis. Journal of Clinical
Microbiology 42, 164–171.
Page 11 of 23
2004
2004
2004
2004
2004
2004
2004
2004
2004
2003
2003
2003
Odds, F.C., Motyl, M., Andrade, R., Bille, J., Cantón, E., CuencaEstrella, M., Davidson, A., Durussel, C., Ellis, D., Foraker, E.,
Fothergill, A.W., Ghannoum, M.A., Giacobbe, R.A., Gobernado, M.,
Handke, R., Laverdière, M., Lee-Yang, W., Merz, W.G. OstroskyZeichner, L., Pemán, J., Perea1, S., Perfect, J.R., Pfaller, M.A., Proia,
L., Rex, J.H., Rinaldi, M.G., Rodriguez-Tudela, J.-L., Schell, W.,
Shields, C., Sutton, D.A., Verweij, P.E., Warnock, D.W. Susceptibility
testing with caspofungin against Candida and Aspergillus species: an interlaboratory comparison. Journal of Clinical Microbiology 42, 3475–3482.
Odds, F.C., Ausma, J., Van Gerven, F., Woestenborghs, F., Meerpoel,
L., Heeres, J., Vanden Bossche, H., Borgers M. In vitro and in vivo
activities of the novel azole antifungal agent R126638. Antimicrobial
Agents and Chemotherapy 48, 388-391.
MacCallum, D.M., Odds, F.C. Safety aspects of working with Candida
albicans-infected mice. Medical Mycology 42, 305-309.
MacCallum, D.M., Odds, F.C. Need for early antifungal treatment
confirmed in experimental disseminated Candida albicans infection.
Antimicrobial Agents and Chemotherapy 48, 4911–4914.
Kelly, M.T., MacCallum, D.M., Odds, F.C., Brown, A.J., Butler, G.
The Candida albicans CaACE2 gene affects morphogenesis, adherence and
virulence. Molecular Microbiology 53, 969–983.
Hobson, R.P., Munro, C.A., Bates, S., MacCallum, D.M., Cutler, J.E.,
Heinsbroek, S.E.M., Brown, G.D., Odds, F.C., Gow, N.A.R. Loss of cell
wall mannosylphosphate in Candida albicans does not influence
macrophage recognition. Journal of Biological Chemistry 279, 39628–
39635.
Galán, A., Casanova, M., Murgui, A., MacCallum, D.M., Odds, F.C.,
Gow, N.A.R., Martínez, J.P. The Candida albicans pH-regulated KER1
gene encodes a lysine/glutamic acid rich plasma-membrane protein that is
involved in cell aggregation. Microbiology 150, 2641-2651.
Brand, A., MacCallum, D.M., Brown, A.J.P., Gow, N.A.R., Odds, F.C.
Ectopic expression of URA3 can influence the virulence phenotypes and
proteome of Candida albicans but can be overcome by targeted reintegration of URA3 at the RPS10 locus. Eukaryotic Cell 3, 900–909.
Barelle, C.J., Manson, C.L., MacCallum, D.M., Odds, F.C., Gow,
N.A.R., Brown, A.J.P. GFP as a quantitative reporter of gene regulation in
Candida albicans. Yeast 21, 333–340.
Tavanti, A., Gow, N.A.R., Senesi, S., Maiden, M.C., Odds, F.C.
Optimization and validation of multi-locus sequence typing for Candida
albicans. Journal of Clinical Microbiology 41, 3765–3776.
Bougnoux, M.-E., Tavanti, A., Couchier, C., Gow, N.A.R., Magnier, A.,
Davidson, A.D., Maiden, M.C.J., d’Enfert, C., Odds, F.C. Collaborative
consensus for optimized multilocus sequence typing of Candida albicans.
Journal of Clinical Microbiology 41, 5265–5266.
Bartizal, C., Odds, F.C. Influence of methodologic variables on
susceptibility testing with caspofungin against Candida species and
Page 12 of 23
Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy 47, 21002107.
2002
MacCallum, D.M., Odds, F.C. Influence of grapefruit juice on
itraconazole plasma levels in mice and guinea pigs. Journal of
Antimicrobial Chemotherapy 50, 219–224.
2002
MacCallum, D.M., Odds, F.C. Efficacy of parenteral itraconazole against
disseminated Candida albicans infection in two mouse strains. Journal of
Antimicrobial Chemotherapy 50, 225–229.
2002
Freydière, A.-M. Parant, F., Noel-Baron, F., Crepy, M., Treny, A.,
Raberin, H., Davidson, A., Odds, F.C. Identification of Candida glabrata
by a 30-second trehalase test. Journal of Clinical Microbiology 40, 3602–
3605.
2002
Badoc, C., De Meeus, T., Bertout, S., Odds, F. C., Maillie, M., Bastide,
J. M. Clonality structure in Candida dubliniensis. FEMS Microbiology
Letters 209, 249-254.
2001
Rambali, B., Fernandez, J.A., Van Nuffel, L., Woestenborghs, F.,
Baert, L., Massart, D.L., Odds, F.C. Susceptibility testing of pathogenic
fungi with itraconazole: a process analysis of test variables. Journal of
Antimicrobial Chemotherapy 48, 163–177.
2001
Parant F, Freydière A-M, Gille Y, Boiron P, Odds FC. Identification, en
une minute, des colonies de Candida glabrata par détectation de la
tréhalase. Journale de Mycologie Médicale 11, 26–31.
2001
Murad, A.M.A, Leng, P., Straffon, M., Wishart, J., Macaskill, S.,
MacCallum, D., Schnell, N., Talibi, D., Marechal, D., Tekaia, F.,
d’Enfert, C., Gaillardin, C., Odds, F.C., Brown, A.J.P. NRG1 represses
yeast-hypha morphogenesis and hypha-specific gene expression in Candida
albicans. The EMBO Journal 20, 4742–4752.
2001
Freydière, A.M., Odds, F.C. Commercial kits for yeast identification:
concerns for standardization. European Journal of Clinical Microbiology
& Infectious Diseases 20, 366–367.
2000
Saha, A.K., Liu, L., Simoneaux, R.L., Kukla, M.J., Marichal, P., Odds,
F. Novel antifungals based on 4-substituted imidazole: a combinatorial
chemistry approach to lead discovery and optimization. Bioorganic &
Medicinal Chemistry Letters. 10, 2175–2178.
2000 Saha, A.K., Liu, L., Marichal, P., Odds, F. Novel antifungals based on 4substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides
towards optimization of in vitro activity. Bioorganic & Medicinal
Chemistry Letters. 10, 2735–2739.
2000
Odds, F.C., Vanden Bossche, H. Antifungal activity of itraconazole
compared with hydroxy-itraconazole in vitro. Journal of Antimicrobial
Chemotherapy 45, 371–374..
2000
Odds, F.C., Van Nuffel, L., Gow N.A.R. Survival in experimental
Candida albicans infections depends on inoculum growth conditions as
well as animal host. Microbiology 146, 1881–1889.
2000
Odds, F.C., Oris, M., Van Dorsselaer, P., Van Gerven, F. Activity of an
intravenous formulation of itraconazole in experimental disseminated
Page 13 of 23
2000
2000
1999
1999
1999
1999
1999
1998
1998
1998
1998
Aspergillus, Candida and Cryptococcus infections. Antimicrobial Agents
and Chemotherapy 44, 3180–3183.
Odds, F.C., Davidson, A. “Room temperature” use of CHROMagar
Candida®. Diagnostic Microbiology and Infectious Disease 38, 147–150.
De Backer, M.D., de Hoogt, R.A., Froyen, G., Odds, F.C., Simons, F.,
Contreras, R., Luyten, W.H.M.L. Single allele knock-out of Candida
albicans CGT1 leads to unexpected resistance to hygromycin B and
elevated temperature. Microbiology 146, 353–365.
Overdijk, B., Van Steijn, G.J., Odds, F.C. Distribution of chitinase in
guinea pig tissues and increases in levels of this enzyme after systemic
infection with Aspergillus fumigatus. Microbiology 145, 259–269.
Odds, F.C., Dupont, B., Rinaldi, M.G., Stevens, D.A., Warnock, D.W.,
Woestenborghs, R. Bioassays for itraconazole blood levels: an interlaboratory collaborative study. Journal of Antimicrobial Chemotherapy 43,
723–727.
Meis, J.F.G.M., Ruhnke, M., De Pauw, B.E., Odds, F.C., Seigert, W.,
Verweij, P.E. Candida dubliniensis candidemia in patients with
chemotherapy induced neutropenia and bone marrow transplantation.
Emerging Infectious Diseases 5, 150–153.
Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P.,
Luyten, W., Borgers, M., Ramaekers, F.C.S., Odds, F.C., Vanden
Bossche, H. Contribution of mutations in the cytochrome P450 14demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.
Microbiology 145, 2701–2713.
Marichal, P., Gorrens, J., Laurijssens, L., Vermuyten, K., Van Hove,
C., Le Jeune, L., Verhasselt, P., Sanglard, D., Borgers, M., Ramaekers,
F.C.S., Odds, F.C., Vanden Bossche, H. Accumulation of 3-ketosteroids
induced by itraconazole in azole-resistant clinical Candida albicans
isolates. Antimicrobial Agents and Chemotherapy 43, 2663–2670.
Schoofs, A., Odds, F.C., Colebunders, R., Ieven, M., Goossens, H.
Cross-sectional study of oral Candida carriage in HIV-seropositive
population: predisposing factors, epidemiology and antifungal
susceptibility. Mycoses 41, 203–211.
Odds, F.C., Van Nuffel, L., Dams, G. Prevalence of Candida dubliniensis
isolates in a yeast stock collection. Journal of Clinical Microbiology 36,
2869–2873..
Odds, F.C., Van Gerven , F., Espinel-Ingroff, A., Bartlett, M.S.,
Galgiani, J.N., Ghannoum, M.A., Lancaster, M.V., Pfaller, M.A., Rex,
J.H., Rinaldi, M.G., Walsh, T.J. Evaluation of possible correlations
between antifungal susceptibilities of filamentous fungi in vitro and
antifungal treatment outcomes in animal infection models. Antimicrobial
Agents and Chemotherapy 42, 282–288.
Hube B., Sanglard, D., Schaller, M., Ibrahim, A., Odds, F.C., Gow,
N.A.R. Welche Funktionen heben sechs verscheidene Gene für
sekretorische Proteinasen von Candida albicans? Mycoses 41 (suppl. 1),
47–50.
Page 14 of 23
1998
Buurman, E.T., Westwater, C., Hube, B., Brown, A.J.P., Odds, F.C.,
Gow, N.A.R. Molecular analysis of CaMnt1p, a mannosyl transferase
important for adhesion and virulence of Candida albicans. Proceedings of
the National Academy of Sciences USA 95, 7670–7675.
1998
Arrese, J.E., De Doncker, P., Odds, F.C., Pierard, G.E. Reduction in the
growth of non-dermatophyte moulds by itraconazole: evaluation by
corneofungimetry assay. Mycoses. 41, 461–465.
1997
Schoofs, A., Odds, F.C., Colebunders, R., Ieven, M., Wouters, L.,
Goossens, H. Isolation of Candida species on media with and without
added fluconazole reveals high variability in relative growth susceptibility
phenotypes. Antimicrobial Agents and Chemotherapy 41, 1625–1635.
1997 Schoofs, A., Odds, F.C., Colebunders, B., Ieven, G., Goossens, H.
Recognition and identification of Candida dubliniensis isolates from HIV
patients: use of specialized isolation media. European Journal of Clinical
Microbiology and Infectious Diseases 16, 296–300.
1997 Sanglard, D., Hube, B., Monod, M., Gow, N.A.R., Odds, F.C. A triple
deletion of the secretory aspartyl protease genes SAP4, SAP5, SAP6 causes
attenuated virulence in Candida albicans. Infection and Immunity 65,
3539–3546.
1997 Rex, J.H., Pfaller, M.A., Galgiani, J.N., Bartlett, M.S., Espinel-Ingroff,
A., Ghannoum, M.A., Lancaster, M., Odds, F.C., Rinaldi, M.G., Walsh,
T.J., Barry, A.L. Development of interpretive breakpoints for antifungal
susceptibility testing: conceptual framework and analysis of in vitro-in vivo
correlation data for fluconazole, itraconazole, and Candida infections.
Clinical Infectious Diseases 24, 235–247.
1997 Reichard, U., Monod, M., Odds, F.C., Rüchel, R. Virulence of an
aspergillopepsin-deficient mutant of Aspergillus fumigatus and evidence for
another aspartic proteinase linked to the fungal cell wall. Journal of
Medical and Veterinary Mycology 35, 189–196.
1997 Odds, F.C., Rinaldi, M.G., Cooper, C.R. Jr., Fothergill, A., Pasarell, L.,
McGinnis, M.R. Candida and Torulopsis: a blinded evaluation of use of
pseudohypha formation as basis for identification of medically important
yeasts. Journal of Clinical Microbiology 35, 313–316.
1997 Marichal, P., Vanden Bossche, H., Odds, F.C., Nobels, G., Warnock, D.W.,
Timmerman, V., Fay, S., Møse-Larsen, P. Molecular biological
characterization of an azole-resistant Candida glabrata isolate.
Antimicrobial Agents and Chemotherapy 41, 2229–2237.
1997 Hube, B., Sanglard, D., Odds, F.C., Hess, D., Monod, M., Schäfer, W.,
Brown, A.J.P., Gow, N.A.R. Disruption of each of the secretory aspartyl
proteinase genes SAP1, SAP2 and SAP3 in Candida albicans attenuates
virulence. Infection and Immunity 65, 3529–3538.
1997 Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N.X., Cooper, C.R., Jr.,
Fothergill, A., McGinnis, M.R., Menezes, P., Messer, S.A., Nelson,
P.W., Odds, F.C., Pasarell, L., Peter, J., Pfaller, M.A., Rex, J.H.,
Rinaldi, M.G., Shankland, G., Walsh, T.J., Weitzmann, I. Multicenter
evaluation of proposed standardized procedure for antifungal susceptibility
Page 15 of 23
1996
1996
1996
1996
1996
1996
1995
1995
1995
1995
1995
1994
testing of filamentous fungi. Journal of Clinical Microbiology 35, 139–
143.
Rex, J.H., Pfaller, M.A., Lancaster, M., Odds, F.C., Bolmström, A., Rinaldi,
M.G. Quality control guidelines for National Committee for Clinical
Laboratory Standards recommended broth macrodilution testing of
ketoconazole and itraconazole. Journal of Clinical Microbiology 34, 816–
817.
Pfaller, M.A., Messer, S.A., Bolmström, A, Odds, F.C., Rex, J.H. Multisite
reproducibility of the Etest agar diffusion MIC method for antifungal
susceptibility testing of yeast isolates. Journal of Clinical Microbiology 34,
1691–1693.
Overdijk, B., Van Steijn, G.J., Odds, F.C. Chitinase levels in guinea pig blood
are increased after systemic infection with Aspergillus fumigatus.
Glycobiology 6, 627–634.
Odds, F.C., Dams, G., Lewi, P. Susceptibilities of Candida species to
antifungal agents visualized by two-dimensional relative growth
scatterplots. Antimicrobial Agents and Chemotherapy 40, 588–594.
De Doncker, P., Decroix, J., Piérard, G.E., Roelant, D., Woestenborghs, R.,
Jacqmin, P., Odds, F., Heremans, A/, Dockx, P/, Roseeuw, D.
Antifungal pulse therapy in onychomycosis: a
pharmacokinetic/pharmacodynamic evaluation of monthly cycles of 1 week
pulse with itraconazole. Archives of Dermatology 132, 34–41.
De Doncker, P., Decroix, J., Pierard, G.E., Roelant, D., Woestenborghs, R.,
Jacqmin, P., Odds, F., Heremans, A., Dockx, P., Roseeuw, D.
Antifungal pulse therapy for onychomycosis. A pharmacokinetic and
pharmacodynamic investigation of monthly cycles of 1-week pulse therapy
with itraconazole. Archives of Dermatology 132, 34–41.
Van Gerven, F., Odds, F.C. The anti-Malassezia furfur activity in vitro and in
experimental dermatitis of six imidazole antifungal agents: bifonazole,
clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole.
Mycoses 38, 389–393.
Odds, F.C., Vranckx, L, Woestenborghs, F. Antifungal susceptibility testing
of yeasts: evaluation of technical variables for test automation.
Antimicrobial Agents and Chemotherapy 39, 2051–2060.
Odds, F.C., De Backer, T., Dams, G., Vranckx, L., Woestenborghs, F.
Oxygen as limiting nutrient for growth of Cryptococcus neoformans.
Journal of Clinical Microbiology 33, 995-997.
Louwagie, B.M-L., Surmont, I., Verhaegen, J., Odds F.C. Differential and
enrichment media for selective culture and recognition of yeasts from
clinical material. European Journal of Clinical Microbiology and
Infectious Diseases 14, 406-411.
Ginter, G., de Hoog, G.S., Pschaid, A., Fellinger, M., Bogiatzis, A., Berghold,
C., Reich, E.M., Odds, F.C. Arthritis without grains caused by
Pseudallescheria boydii. Mycoses 38, 369–371.
Odds, F.C., Bernaerts, R. CHROMagar® Candida, a new, differential
isolation medium for the presumptive identification of clinically important
Candida species. Journal of Clinical Microbiology 32, 1923-1929.
Page 16 of 23
1993 Odds, F.C., Baeten, B. Coremans, G. Van Cutsem, J. De Beule, K.,
Cauwenbergh, G. Clinical experiences with itraconazole in vaginal
Candida infections. International Journal of Feto-Maternal Medicine 5,
147-149.
1993 Odds, F.C. Effects of temperature on anti-Candida activity of antifungal
antibiotics. Antimicrobial Agents and Chemotherapy 37, 685-691.
1993 Fromtling, R.A., Galgiani, J.N., Pfaller, M.A., Espinel-Ingroff, A., Bartizal,
K., Bartlett, M.S., Body, B.A., Frey, C. Hall, G. Roberts, G.D., Nolte,
R., Odds, F.C., Rinaldi, M.G., Sugar, A.M., Villareal, K. Multicenter
evaluation of a macrobroth antifungal susceptibility test for yeasts.
Antimicrobial Agents and Chemotherapy 37, 39-45.
1992 Xhonneux, B., Jansen, T., Borgers, M., Odds, F.C. Effects of itraconazole on
phagocytosis and killing of Candida glabrata by polymorphonuclear
leukocytes from guinea pigs. Journal of Antimicrobial Chemotherapy 30,
181-188.
1992 Vanden Bossche, H., Marichal, P., Odds, F.C., Le Jeune, L., Coene, M.-C.
Characterization of an azole-resistant Candida glabrata isolate.
Antimicrobial Agents and Chemotherapy 36, 2602-2610.
1992 Sharp, A.M., Evans, E.G.V., Odds, F.C. Species and biotypes of Candida
from neonates in a prospective study of a special care baby unit. Archives
of Disease in Childhood 67, 48-52.
1992 Schmid, J., Odds, F.C., Wiselka, M.W., Nicholson, K.G., Soll, D.R.
Genetic similarity and maintenance of Candida albicans strains from a
group of AIDS patients, demonstrated by DNA fingerprinting. Journal of
Clinical Microbiology 30, 935-941.
1992 Odds, F.C., Arai, T., DiSalvo, A.F., Evans, E.G.V., Hay, R.J., Randhawa,
H.S., Rinaldi, M.G., Walsh, T.J. Nomenclature of fungal diseases: a
report and recommendations from a Sub-Committee of the International
Society for Human and Animal Mycology (ISHAM). Journal of Medical
and Veterinary Mycology 30, 1-10.
1992 Odds, F.C. Antifungal susceptibility testing of Candida species by relative
growth measurement at single concentrations of antifungal agents.
Antimicrobial Agents and Chemotherapy 36, 1727-1737.
1992 Merson-Davies, L.A., Odds, F.C. Expansion of the Candida albicans cell
envelope in different morphological forms of the fungus. Journal of
General Microbiology 138, 461-466.
1991 Van Cutsem, J., Van Gerven, F., Cauwenbergh, G., Odds, F., Janssen, P.A.J.
The anti-inflammatory effects of ketoconazole: a comparative study with
hydrocortisone acetate in a model using living and killed Staphylococcus
aureus on the skin of guinea-pigs. Journal of the American Academy of
Dermatology 25, 257-261.
1991 Odds, F.C. Long-term preservation of pathogenic yeasts under distilled water.
Journal of Medical and Veterinary Mycology 29, 413-415.
1991 Odds, F.C. A quantitative microculture system with standardized inocula for
strain typing, susceptibility testing and other physiologic measurements
Page 17 of 23
1991
1991
1991
1991
1991
1991
1990
1990
1990
1990
1990
1989
with Candida albicans and other yeasts Journal of Clinical Microbiology
29, 2735-2740.
Merson-Davies, L.A., Malet, R., Young, S., Riley, V.C., Schober, P., Fisk,
P.G., Odds, F.C. Quantification of Candida albicans morphology in
vaginal smears. European Journal of Obstetrics, Gynecology and
Reproductive Biology 42, 49-52.
Merson-Davies, L.A., Hopwood, V., Robert, R., Marot-Leblond, A., Senet,
J.-M., Odds, F.C. Reaction of Candida albicans cells of different
morphology index with monoclonal antibodies specific for the hyphal form.
Journal of Medical Microbiology 35,.321-324.
Jansen, T.M., Van de Ven, M.A.A., Borgers, M., Odds, F.C., Van Cutsem, J.
Fungal morphology after treatment with itraconazole as a single oral dose in
experimental vaginal candidosis in rats. American Journal of Obstetrics
and Gynecology 165, 1552-1557.
Hube, B., Turver, C.J., Odds, F.C., Eiffert, H., Boulnois, G.J., Köchel, H.,
Rüchel, R. Sequence of the Candida albicans gene encoding the secretory
aspartate proteinase. Journal of Medical and Veterinary Mycology 29, 129132.
Hube, B., Turver, C.J., Odds, F.C., Eiffert, H., Boulnois, G.J., Köchel, H.,
Rüchel, R. Identifizierung, Klonierung und Charakterisierung des Gens
der sekretorischen Aspartat-Protease von Candida albicans . Mycoses 34
(suppl.), 59-61.
Mackenzie, D.W.R., Odds, F.C. Non-identity and authentication of two major
reference strains of Candida albicans. Journal of Medical and Veterinary
Mycology 29, 255-261.
Pfaller, M.A., Rinaldi, M.G., Galgiani, J.N., Bartlett, M.S., Body, B.A.,
Espinel-Ingroff, A., Fromtling, R.A., Hall, G.S., Hughes, C.E., Odds,
F.C., Sugar, A.M. Collaborative investigation of variables in antifungal
susceptibility testing of yeasts. Antimicrobial Agents and Chemotherapy
34, 1648-1654.
Stevens, D.A., Odds, F.C., Scherer, S. Application of DNA typing methods to
Candida albicans epidemiology and correlations with phenotype. Reviews
of Infectious Diseases 12, 258-266.
Odds, F.C., Sackin, M.J., Jones, D. Numerical taxonomic analysis of imperfect
species in Candida and Torulopsis shows no basis for generic separation.
Journal of General Microbiology 136, 761-765.
Montague, W., Odds, F.C. Academic selection criteria and subsequent
performance. Medical Education 24, 151-157.
Fruit, J., Caillez, J.C., Odds, F.C., Poulain, D. Expression of an antigenic
epitope by surface glycoproteins of Candida albicans: variability among
species, strains and yeast cells of the genus Candida . Journal of Medical
and Veterinary Mycology 28, 241-252.
Odds, F.C., Webster, C.E., Fisk, P.G., Riley, V.C., Mayuranathan, P.,
Simmons, P.D. Candida species and C. albicans biotypes in women
attending clinics in genitourinary medicine. Journal of Medical
Microbiology 29, 51-54.
Page 18 of 23
1989 Odds, F.C., Merson-Davies, L.A. Colony variations in Candida species.
Mycoses 32, 275-282.
1989 Odds, F.C., Kibbler, C.C., Walker, E., Bhamra, A., Prentice, H.G., Noone, P.
Carriage of Candida species and C. albicans biotypes in patients
undergoing chemotherapy or bone marrow transplantation for
haematological diseases. Journal of Clinical Pathology 42, 1259-1266.
1989 Odds, F.C., Auger, P., Krogh, P., Neely, A.N., Segal, E. Biotyping of Candida
albicans: results of an international collaborative survey. Journal of
Clinical Microbiology 27, 1506-1509.
1989 Odds, F.C. Antifungal action of saperconazole (R 66905) in vitro. Journal of
Antimicrobial Chemotherapy 24, 533-537.
1989 Merson-Davies, L.A., Odds, F.C. A morphology index for estimation of cell
shape in Candida albicans. Journal of General Microbiology 135, 31433152.
1989 Kibbler, C.C., Odds, F.C. Fluconazole versus ketoconazole in oropharyngeal
candidosis in AIDS. Lancet 1, 1130.
1989 Abbott, A.B., Odds, F.C. Abrogation by glucose of the ATP suppression
induced by miconazole in Candida albicans. Journal of Antimicrobial
Chemotherapy 24, 905-919.
1988 Page, S., Odds, F.C. Binding of plasma proteins to Candida species in vitro.
Journal of General Microbiology 134, 2693-2702.
1988 Odds, F.C., Webster, C.E., Mayuranathan, P., Simmons, D. Candida
concentrations in the vagina and their association with signs and symptoms
of vaginal candidosis Journal of Medical and Veterinary Mycology 26, 277282.
1988 Odds, F.C., Webster, C.E. Effects of azole antifungals in vitro on host/parasite
interactions relevant to Candida infections. Journal of Antimicrobial
Chemotherapy 22, 473-481.
1988 Odds, F.C. Standardization of MIC tests for antifungals against Candida
species. In: J.M. Torres-Rodriguez (ed.) Proceedings of the X Congress of
the International Society for Human and Animal Mycology-ISHAM, pp.
210-212. J.R. Prous, S.A., Barcelona.
1988 Odds, F.C. Activity of cilofungin (LY 121019) against Candida species in vitro.
Journal of Antimicrobial Chemotherapy 22, 891-897.
1988 Neely, A.N., Odds, F.C., Basatia, B.K., Holder, I.A. Characterization of
Candida isolates from pediatric burn patients. Journal of Clinical
Microbiology 26, 1645-1649.
1987 Webster, C.E., Odds, F.C. Growth of pathogenic Candida isolates
anaerobically and under elevated concentrations of CO2 in air. Journal of
Medical and Veterinary Mycology 25, 47-53.
1987 Odds, F.C., Webster, C.E., Riley, V.C., Fisk, P.G. Epidemiology of vaginal
Candida infection: significance of numbers of vaginal yeasts and their
biotypes. European Journal of Obstetrics, Gynecology and Reproductive
Biology 25, 53-66.
Page 19 of 23
1987 Odds, F.C., Palacio-Hernanz, A., Cuadra, J., Sanchez, J. Disseminated
Candida infection syndrome in heroin addicts - dominance of a single
Candida albicans biotype. Journal of Medical Microbiology 23, 275-277.
1987 Miro, J.M., Puig de la Bellacasa, J., Odds, F.C., Gill, B.K., Bisbe, J., Gatell,
J.M., Gonzalez, J., Latorre, X., Jiminez de Anta, M.T., Soriano, E.,
Garcia San Miguel, J. Systemic candidiasis in Spanish heroin addicts: a
possible source of infection. Journal of Infectious Diseases 156, 857-858.
1987 Miro, J.M., Palacio Hernanz, A., Martinez Ortiz de Zarate, M., de la
Cuadra, J., Odds, F.C. Predominio de Candida albicans serotipo A, biotip
153/7 en los brotes de candidiasis diseminada en heroinomanos en Espana.
Medicina Clinica 89, 38.
1986 Sevilla, M.-J., Odds, F.C. Development of Candida albicans hyphae in different
growth media - variations in growth rates, cell dimensions and timing of
morphogenetic events. Journal of General Microbiology 132, 3083-3088.
1986 Sevilla, M.-J., Odds, F.C. Consistency of protein patterns in Candida albicans
during hyphal septum and branch formation. Journal of Medical and
Veterinary Mycology 24, 419-422.
1986 Riley, V.C., Odds, F.C., Fisk, P.E., Webster, C.E. Finger nails as a reservoir
for Candida albicans in recurrence of vaginal candidosis. Genitourinary
Medicine 62, 358.
1986 Odds, F.C., Cheesman, S.L., Abbott, A.B. Antifungal effects of fluconazole
(UK 49858), a new triazole antifungal, in vitro. Journal of Antimicrobial
Chemotherapy 18, 473-478.
1986 Odds, F.C., Abbott, A.B., Pye, G., Troke, P.F. Improved method for
estimation of azole antifungal inhibitory concentrations against Candida
species, based on azole/antibiotic interactions. Journal of Medical and
Veterinary Mycology 24, 305-311.
1985 Polak, A., Odds, F.C., Ludin, E., Scholer, H.J. Correlation of susceptibility
test results in vitro with response in vivo: ketoconazole therapy in a
systemic candidiasis model. Chemotherapy 31, 395-404.
1985 Odds, F.C., Cockayne, A., Hayward, J., Abbott, A.B. Effects of imidazoleand triazole-derivative antifungal compounds on the growth and
morphological development of Candida albicans hyphae. Journal of
General Microbiology 131, 2581-2589.
1985 Odds, F.C., Cheesman, S.L., Abbott, A.B. Suppression of ATP in Candida by
imidazole- and triazole-derivative antifungal agents. Sabouraudia: Journal
of Medical and Veterinary Mycology 23, 415-424.
1985 Burnie, J.P., Odds, F.C., Lee, W., Webster, C., Williams, J.D. Outbreak of
systemic Candida albicans in intensive care unit caused by cross infection.
British Medical Journal 290, 746-748.
1985 Burnie, J.P., Matthews, R.C., Lee, W., Odds, F.C., Williams, J.D. Control of
an outbreak of systemic Candida albicans. British Medical Journal 291,
1092.
1985 Anderson, M.L., Odds, F.C. Adherence of Candida albicans to vaginal
epithelia: significance of morphological form and effect of ketoconazole.
Mykosen 28, 531-540.
Page 20 of 23
1984 Working Group of the British Society for Mycopathology. Laboratory
methods for flucytosine (5-fluorocytosine). Journal of Antimicrobial
Chemotherapy 14, 1-8.
1984 Odds, F.C., Webster, C.E., Abbott, A.B. Antifungal relative inhibition factors:
BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R
51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and
vibunazole (BAY n-7133) compared in vitro with nine established
antifungal agents. Journal of Antimicrobial Chemotherapy 14, 105-114.
1984 Odds, F.C., Abbott, A.B. Relative inhibition factors - a novel approach to the
assessment of antifungal antibiotics in vitro. Journal of Antimicrobial
Chemotherapy 13, 31-43.
1984 Odds, F.C. Demonstration of a septal pore in yeast cells of Candida albicans.
Sabouraudia: Journal of Medical and Veterinary Mycology 22, 505-507.
1984 Cockayne, A., Odds, F.C. Interactions of Candida albicans yeast cells, germ
tubes and hyphae with human polymorphonuclear leukocytes in vitro.
Journal of General Microbiology 130, 465-471.
1983 Odds, F.C., Ryan, M.D., Sneath, P.H.A. Standardization of antigens from
Aspergillus fumigatus. Journal of Biological Standardization 11, 157-162.
1983 Odds, F.C., Abbott, A.B., Stiller, R.L., Scholer, H.J., Polak, A., Stevens, D.A.
Analysis of Candida albicans phenotypes from different geographical and
anatomical sources. Journal of Clinical Microbiology 18, 849-857.
1983 Odds, F.C., Abbott, A.B., Reed, T.A.G., Willmott, F.E. Candida albicans
strain types from the genitalia of patients with and without Candida
infection. European Journal of Obstetrics and Gynecology 15, 37-43.
1983 Odds, F.C., Abbott, A.B. Modification and extension of tests for differentiation
of Candida species and strains. Sabouraudia 21, 79-81.
1983 Macdonald, F., Odds, F.C. Virulence for mice of a proteinase-secreting strain
of Candida albicans and a proteinase-deficient mutant. Journal of General
Microbiology 129, 431-438.
1982 Odds, F.C. Ketoconazole resistance. The Lancet ii, 771.
1982 Odds, F.C. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole
and miconazole against pathogenic fungi in vitro. Antimicrobial Agents
and Chemotherapy 22, 763-775.
1982 Odds, F.C. Genital candidosis. Clinical and Experimental Dermatology 7, 345354.
1981 Odds, F.C., Macdonald, F. Persistence of miconazole in vaginal secretions
after single applications of the antifungal: implications for the treatment of
vaginal candidosis. British Journal of Venereal Diseases 57, 400-401.
1981 Odds, F.C. Persistence of miconazole in saliva after a single oral dose. Clinical
Research Reviews 1, 231-232.
1980 Odds, F.C., Gentles, J.C., Milne, L.J.R., Ball, E.H. Activity in vitro and in
vivo of a new imidazole antifungal, ketoconazole. Journal of Antimicrobial
Chemotherapy 6, 97-104.
Page 21 of 23
1980 Odds, F.C., Evans, E.G.V. Distribution of pathogenic yeasts and humoral
antibodies to Candida among hospitalized patients. Journal of Clinical
Pathology 33, 750-756.
1980 Odds, F.C., Abbott, A.B. A simple system for the presumptive identification of
Candida albicans and differentiation of strains within the species.
Sabouraudia 18, 301-318.
1980 Odds, F.C. Laboratory evaluation of antifungal agents: a comparison of five
imidazole derivatives of clinical importance. Journal of Antimicrobial
Chemotherapy 6, 749-761.
1980 Macdonald, F., Odds, F.C. Inducible proteinase of Candida albicans in
diagnostic serology and in the pathogenesis of systemic candidosis. Journal
of Medical Microbiology 13,423-435.
1980 Macdonald, F., Odds, F.C. Purified Candida albicans proteinase in the
serological diagnosis of systemic candidosis. Journal of the American
Medical Association 243, 2409-2411.
1980 Clarke, M., Davies, D.P., Odds, F.C., Mitchell, C. Neonatal systemic
candidiasis treated with miconazole. British Medical Journal 2, 354.
1979 Odds, F.C. Problems in the laboratory assessment of antifungal activity.
Postgraduate Medical Journal 55, 677-680.
1978 Taylor, C.F., Watkins, J.D., Odds, F.C., Gough, D.A. A comparative study of
the effectiveness of two antifungal agents in treating athlete's foot. British
Journal of Clinical Practice (spl.) 8-12.
1978 Odds, F.C., Hall, C.A., Abbott, A.B. Peptones and mycological reproducibility.
Sabouraudia 16, 237-246.
1978 Odds, F.C., Evans, E.G.V., Taylor, M.A.R., Wales, J.K. Prevalence of
pathogenic yeasts and humoral antibodies to Candida in diabetic patients.
Journal of Clinical Pathology 3, 840-844.
1977 Odds, F.C. Cure and relapse with antifungal therapy. Proceedings of the Royal
Society of Medicine 20 (spl. 4), 24-28.
1975 Odds, F.C., Evans, E.G.V., Holland, K.T. Detection of Candida precipitins. A
comparison of double diffusion and counter-immuno–electrophoresis.
Journal of Immunological Methods 7, 211-218.
1975 Odds, F.C., Evans, E.G.V. Routine use of a modified Sabouraud's dextrose
broth in the germ tube test for Candida albicans. Medical Laboratory
Technology 32, 23-36.
1975 Evans, E.G.V., Odds, F.C., Holland, K.T. Resistance of the Candida albicans
filamentous cycle to environmental change. Sabouraudia 13, 231-238.
1975 Evans, E.G.V., Odds, F.C., Holland, K.T. Optimum conditions for initiation of
filamentation in Candida albicans. Canadian Journal of Microbiology 21,
338-342.
1974 Odds, F.C., Trujillo-Gonzalez, A. Acid phosphatase levels in the genus
Candida and their application to the taxonomy and identification of
Candida species. Sabouraudia 12, 287-294.
1974 Odds, F.C., Kaufman, L., McLaughlin, D., Callaway, C., Blumer, S.O. Effect
of chitinase complex and beta-1:3-glucanase on the antigenicity and
Page 22 of 23
1974
1973
1973
1973
1973
1971
1969
2005
2004
2004
2003
2002
2000
2000
1999
chemistry of yeast-form cells and other fractions of Histoplasma
capsulatum and Blastomyces dermatitidis. Sabouraudia 12, 138-149.
Evans, E.G.V., Odds, F.C., Richardson, M.D., Holland, K.T. The effect of
growth medium on filament production in Candida albicans. Sabouraudia
12, 112-119.
Odds, F.C., Hierholzer, J.C. Purification and properties of a glycoprotein acid
phosphatase from Candida albicans. Journal of Bacteriology 114, 257-266.
Odds, F.C. Spirolaterals. The Mathematics Teacher 66, 121-124.
Evans, E.G.V., Richardson, M.D., Odds, F.C., Holland, K.T. Relevance of
antigenicity of Candida albicans growth phases to diagnosis of systemic
candidiasis. British Medical Journal 4, 86-87.
Chattaway, F.W., Bishop, R., Holmes, M.R., Odds, F.C., Barlow, A.J.E.
Enzyme activities associated with carbohydrate synthesis and breakdown in
the yeast and mycelial forms of Candida albicans. Journal of General
Microbiology 75, 97-109.
Chattaway, F.W., Odds, F.C., Barlow, A.J.E. An examination of the
production of hydrolytic enzymes and toxins by pathogenic strains of
Candida albicans. Journal of General Microbiology 67, 255-263.
Chattaway, F.W., Hullin, R.P., Odds, F.C. The variability of creatinine
excretion in normal subjects, mental patients and pregnant women. Clinica
Chimica Acta 26, 567-576.
Patents/Patent Applications
Vernier, D.F.J., Odds, F.C., Gestel, J.F.E., Guillemont, J.E.G., Venet, M.G.,
Poignet, H.J.J., Decrane, L.F.B. quinoline derivatives and their use as
mycobacterial inhibitors. Patent No. WO2004011436
Van Der Veken, L.J.E., Vanden Bossche, H.F.A., Heeres, J., Meerpoel,
L., Odds, F.C. 2,4,4-Trisubstituted-1-3-dioxolanes with antimycotic effect.
Patent no. BG64314.
De Doncker, P.R.G., Odds , F.C., Ho, K., Cauwenbergh, G.F.M.,
Fernandez Candelario, A. Body and or hair cleansing composition and
process for preparing such composition. Patent no. CZ293585.
Backx, L.J.J., Heeres, J., Meerpoel, L., Van Der Veken, L.J.E., Odds,
F.C. Water soluble azoles as broad-spectrum antifungals. Patent no.
SI1077976T.
Backx, L.J.J., Van Der Eycken, L.A.L., Mesens, J.L., Heeres, J., Odds,
F.C. Watersoluble azole antifungals. Patent no. CY2176.
Meerpoel, L.; Heeres, J., Odds, F.C,. Vanden Bossche, H.F.A., Van der
Veken, L.J.E.. 2,4,4-trisubstituted-1,3-dioxolane antifungals. US Patent
no. 6,387,906, application no. 462588. World patent no. WO99/02523.
Meerpoel, L., Backx, L.J.J., Van der Veken, L.J.E., Heeres, J., Odds, F.
Water soluble azoles as broad-spectrum antifungals. US Patent no.
6,384,030 , application no. 700251. World patent no. WO99/58530.
European patent no. EE4311.
Heeres, J., Meerpoel, L. Odds, F.C., Van Der Veken, L.J.E., Vanden
Bossche, H.F.A. 2,4,4-trisubstituted-1,3-dioxolane antifungals. Patent no
CA2295090.
Page 23 of 23
1999
1998
1998
1998
1997
1996
1995
1994
1994
1994
Embrechts, R.C.A., Odds, F.C., De Doncker, P.R.G. compositions
containing an antifungal and a phospholipid. US Patent application no.
20020058059. World patent application no. 97201101.9.
Odds, F.C., Ho, K.L., Cauwenbergh, G.F., Fernandez Candelario, A.
Methods for using compositions containing dichlorophenyl
imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and
acne, and compositions thereof. Patent no. CA2294804.
Odds, F.C., Embrechts, R.C.A., De Doncker, P, Gudula, R.
Compositions containing an antifungal and a cationic agent. US Patent no.
6,207,142, application no. 403057. World patent no. WO98/46207. Patent
no. DE69806577T.
Odds, F.C., De Doncker, P.R.G., Ho, K., Fernandez Candelario, A.,
Cauwenbergh, G.F.M. Compositions containing an antifungal and a
sulfur compound. Patent no. WO9729733.
Heeres, J., Mostmans, J.H., Van Der Eycken, L.A.L., Odds, F.C.,
Stokbroekx, R.A., Van der Aa, M.J.M. Substituted azolone derivatives
[with anti-Helicobacter activity]. US Patent no. 5,650,411, application no.
491960. World patent no. WO94/18978.
Venet, M.G., Guillemont, J.E.G., Vernier, D.F.J., Odds, F.C. 4quinolinyl derivatives with anti-Helicobacter activity. US Patent no.
5,589,484 , application no. 428176. World patent no. WO94/10164.
Heeres, J., Backx, L.J.J., Van der Eycken, L.A.L. Odds, F.C., Mesens,
J.L. Watersoluble azole antifungals. US Patent no. 5,707,977, application
no. 666270. World patent no. WO95/19983.
Venet, M.G., Guillemont, J.E.G., Vernier, D.F.J., Odds, F.C. 4quinolinyl derivatives. US Patent no. 5,589,484, application no. 428176.
World patent no. WO94/10164.
Odds, F.C., Venet, M.G., Guillemont, J.E., Vernier, D.F.J. 4-quinolinyl
derivatives with anti-Helicobacter activity. Patent no. CA2146651.
Heeres, J., Mostmans, J.H., Van Der Eycken, L.A.L. Odds, F.C.,
Stokbroekx, R.A., Van der Aa, M.J.M. Substituted azolone derivatives.
US Patent no. 5,650,411, application no. 491960. World patent no.
WO94/18978.